Profile of Patients with Diabetes Treated with Insulin Lispro 200 U/ml: A Real-World Study from Spain View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-04-21

AUTHORS

Miriam Rubio de Santos, Esther Artime, Natalia Duque, Silvia Díaz-Cerezo, Erik Spaepen, Ágata Carreño, Alberto Fernández

ABSTRACT

IntroductionInsulin lispro 200 U/ml (IL200) is a rapid-acting concentrated insulin used for the treatment of adults with diabetes requiring daily doses of > 20 units of rapid-acting insulin. The aim of this study was to describe the clinical/demographic and treatment characteristics of patients who initiated insulin IL200 therapy in Spain in a real-world setting (PROFILE-IL200).MethodsThis retrospective observational study based on the IQVIA database included adult (≥ 18 years) patients with type 1 (T1D) or type 2 (T2D) diabetes who initiated IL200 between June 2015 and December 2019. Demographic and clinical characteristics were analyzed descriptively.ResultsMain characteristics for the T1D/T2D groups (N = 65/167) were as follows: male, 63.1/55.7%; mean (standard deviation [SD]) age, 46.5 (15.5)/62.6 (12.8) years; time since first diabetes record, 6.6 (4.2)/7.9 (2.9) years; body mass index (BMI), 30.9 (5.8)/33.1 (5.5) kg/m2; glycated hemoglobin, 8.3 (2.1)/8.8 (1.8)%; and diabetes-associated comorbidity, 55.4/92.8%. Among patients with T1D/T2D and a prior diagnosis (N = 54/164), 96.3/90.2% had received previous insulin (rapid insulin in 81.5/62.2%), and 13.0/97.6% had received previous noninsulin antihyperglycemic therapy. The mean (SD) total insulin dose before IL200 initiation for T1D/T2D was 98.0 (73.9)/95.2 (59.8) U/day; IL200 was initiated at a dose of 56.3 (43.8)/51.5 (34.3) U/day, with basal insulin in 86.2/83.2% of the patients. IL200 was first prescribed by an endocrinologist or a primary care physician in 48.7% and 46.6% of patients, respectively.ConclusionsPROFILE-IL200 described the profile of patients treated with IL200 in clinical practice in Spain. Patients were middle-aged, with poor glycemic control, high BMI and associated comorbidities, and received high doses of insulin at IL200 initiation. More... »

PAGES

1147-1160

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-022-01264-6

DOI

http://dx.doi.org/10.1007/s13300-022-01264-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147289631

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35449431


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.476461.6", 
          "name": [
            "Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rubio de Santos", 
        "givenName": "Miriam", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.476461.6", 
          "name": [
            "Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Artime", 
        "givenName": "Esther", 
        "id": "sg:person.07555754123.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07555754123.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.476461.6", 
          "name": [
            "Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Duque", 
        "givenName": "Natalia", 
        "id": "sg:person.01076730565.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076730565.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.476461.6", 
          "name": [
            "Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "D\u00edaz-Cerezo", 
        "givenName": "Silvia", 
        "id": "sg:person.0643342424.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643342424.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "HaaPACS GmbH, Schriesheim, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "HaaPACS GmbH, Schriesheim, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spaepen", 
        "givenName": "Erik", 
        "id": "sg:person.01171720750.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171720750.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IQVIA, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "IQVIA, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carre\u00f1o", 
        "givenName": "\u00c1gata", 
        "id": "sg:person.016704660465.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016704660465.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology and Nutrition, M\u00f3stoles University Hospital, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411171.3", 
          "name": [
            "Department of Endocrinology and Nutrition, M\u00f3stoles University Hospital, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fern\u00e1ndez", 
        "givenName": "Alberto", 
        "id": "sg:person.0730410761.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730410761.59"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2022-04-21", 
    "datePublishedReg": "2022-04-21", 
    "description": "IntroductionInsulin lispro 200 U/ml (IL200) is a rapid-acting concentrated insulin used for the treatment of adults with diabetes requiring daily doses of > 20 units of rapid-acting insulin. The aim of this study was to describe the clinical/demographic and treatment characteristics of patients who initiated insulin IL200 therapy in Spain in a real-world setting (PROFILE-IL200).MethodsThis retrospective observational study based on the IQVIA database included adult (\u2265\u200918\u00a0years) patients with type 1 (T1D) or type 2 (T2D) diabetes who initiated IL200 between June 2015 and December 2019. Demographic and clinical characteristics were analyzed descriptively.ResultsMain characteristics for the T1D/T2D groups (N\u2009=\u200965/167) were as follows: male, 63.1/55.7%; mean (standard deviation [SD]) age, 46.5 (15.5)/62.6 (12.8) years; time since first diabetes record, 6.6 (4.2)/7.9 (2.9) years; body mass index (BMI), 30.9 (5.8)/33.1 (5.5) kg/m2; glycated hemoglobin, 8.3 (2.1)/8.8 (1.8)%; and diabetes-associated comorbidity, 55.4/92.8%. Among patients with T1D/T2D and a prior diagnosis (N\u2009=\u200954/164), 96.3/90.2% had received previous insulin (rapid insulin in 81.5/62.2%), and 13.0/97.6% had received previous noninsulin antihyperglycemic therapy. The mean (SD) total insulin dose before IL200 initiation for T1D/T2D was 98.0 (73.9)/95.2 (59.8) U/day; IL200 was initiated at a dose of 56.3 (43.8)/51.5 (34.3) U/day, with basal insulin in 86.2/83.2% of the patients. IL200 was first prescribed by an endocrinologist or a primary care physician in 48.7% and 46.6% of patients, respectively.ConclusionsPROFILE-IL200 described the profile of patients treated with IL200 in clinical practice in Spain. Patients were middle-aged, with poor glycemic control, high BMI and associated comorbidities, and received high doses of insulin at IL200 initiation.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-022-01264-6", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "body mass index", 
      "profile of patients", 
      "T1D/T2D", 
      "MethodsThis retrospective observational study", 
      "higher body mass index", 
      "diabetes-associated comorbidities", 
      "total insulin dose", 
      "poor glycemic control", 
      "retrospective observational study", 
      "treatment of adults", 
      "primary care physicians", 
      "rapid-acting insulin", 
      "real-world study", 
      "T2D group", 
      "antihyperglycemic therapy", 
      "adult patients", 
      "clinical characteristics", 
      "insulin dose", 
      "basal insulin", 
      "glycemic control", 
      "mass index", 
      "prior diagnosis", 
      "care physicians", 
      "daily doses", 
      "mean age", 
      "treatment characteristics", 
      "diabetes records", 
      "concentrated insulin", 
      "observational study", 
      "previous insulin", 
      "patients", 
      "clinical practice", 
      "type 2", 
      "real-world setting", 
      "high doses", 
      "type 1", 
      "insulin", 
      "comorbidities", 
      "T2D", 
      "diabetes", 
      "therapy", 
      "doses", 
      "dose", 
      "days", 
      "endocrinologists", 
      "initiation", 
      "years", 
      "physicians", 
      "diagnosis", 
      "hemoglobin", 
      "study", 
      "adults", 
      "age", 
      "treatment", 
      "males", 
      "group", 
      "aim", 
      "profile", 
      "setting", 
      "index", 
      "records", 
      "database", 
      "control", 
      "characteristics", 
      "m2", 
      "Spain", 
      "practice", 
      "units", 
      "time"
    ], 
    "name": "Profile of Patients with Diabetes Treated with Insulin Lispro 200 U/ml: A Real-World Study from Spain", 
    "pagination": "1147-1160", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147289631"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-022-01264-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35449431"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-022-01264-6", 
      "https://app.dimensions.ai/details/publication/pub.1147289631"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_937.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-022-01264-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01264-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01264-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01264-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01264-6'


 

This table displays all metadata directly associated to this object as RDF triples.

179 TRIPLES      20 PREDICATES      94 URIs      86 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-022-01264-6 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N70218b5447104317b5ba1b760b1dc2b2
4 schema:datePublished 2022-04-21
5 schema:datePublishedReg 2022-04-21
6 schema:description IntroductionInsulin lispro 200 U/ml (IL200) is a rapid-acting concentrated insulin used for the treatment of adults with diabetes requiring daily doses of > 20 units of rapid-acting insulin. The aim of this study was to describe the clinical/demographic and treatment characteristics of patients who initiated insulin IL200 therapy in Spain in a real-world setting (PROFILE-IL200).MethodsThis retrospective observational study based on the IQVIA database included adult (≥ 18 years) patients with type 1 (T1D) or type 2 (T2D) diabetes who initiated IL200 between June 2015 and December 2019. Demographic and clinical characteristics were analyzed descriptively.ResultsMain characteristics for the T1D/T2D groups (N = 65/167) were as follows: male, 63.1/55.7%; mean (standard deviation [SD]) age, 46.5 (15.5)/62.6 (12.8) years; time since first diabetes record, 6.6 (4.2)/7.9 (2.9) years; body mass index (BMI), 30.9 (5.8)/33.1 (5.5) kg/m2; glycated hemoglobin, 8.3 (2.1)/8.8 (1.8)%; and diabetes-associated comorbidity, 55.4/92.8%. Among patients with T1D/T2D and a prior diagnosis (N = 54/164), 96.3/90.2% had received previous insulin (rapid insulin in 81.5/62.2%), and 13.0/97.6% had received previous noninsulin antihyperglycemic therapy. The mean (SD) total insulin dose before IL200 initiation for T1D/T2D was 98.0 (73.9)/95.2 (59.8) U/day; IL200 was initiated at a dose of 56.3 (43.8)/51.5 (34.3) U/day, with basal insulin in 86.2/83.2% of the patients. IL200 was first prescribed by an endocrinologist or a primary care physician in 48.7% and 46.6% of patients, respectively.ConclusionsPROFILE-IL200 described the profile of patients treated with IL200 in clinical practice in Spain. Patients were middle-aged, with poor glycemic control, high BMI and associated comorbidities, and received high doses of insulin at IL200 initiation.
7 schema:genre article
8 schema:isAccessibleForFree true
9 schema:isPartOf N72e23a81368040d0a6abbbe77b078ac5
10 Na6cf39471be74907b05c1011a3d5d85f
11 sg:journal.1044057
12 schema:keywords MethodsThis retrospective observational study
13 Spain
14 T1D/T2D
15 T2D
16 T2D group
17 adult patients
18 adults
19 age
20 aim
21 antihyperglycemic therapy
22 basal insulin
23 body mass index
24 care physicians
25 characteristics
26 clinical characteristics
27 clinical practice
28 comorbidities
29 concentrated insulin
30 control
31 daily doses
32 database
33 days
34 diabetes
35 diabetes records
36 diabetes-associated comorbidities
37 diagnosis
38 dose
39 doses
40 endocrinologists
41 glycemic control
42 group
43 hemoglobin
44 high doses
45 higher body mass index
46 index
47 initiation
48 insulin
49 insulin dose
50 m2
51 males
52 mass index
53 mean age
54 observational study
55 patients
56 physicians
57 poor glycemic control
58 practice
59 previous insulin
60 primary care physicians
61 prior diagnosis
62 profile
63 profile of patients
64 rapid-acting insulin
65 real-world setting
66 real-world study
67 records
68 retrospective observational study
69 setting
70 study
71 therapy
72 time
73 total insulin dose
74 treatment
75 treatment characteristics
76 treatment of adults
77 type 1
78 type 2
79 units
80 years
81 schema:name Profile of Patients with Diabetes Treated with Insulin Lispro 200 U/ml: A Real-World Study from Spain
82 schema:pagination 1147-1160
83 schema:productId N70d7a496860643b491ea2bc714c1a0e2
84 Nddc5f331f5274f638ac5e596cb32a7d6
85 Ne902d5b6c4374128a5493d3d2e350aa9
86 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147289631
87 https://doi.org/10.1007/s13300-022-01264-6
88 schema:sdDatePublished 2022-08-04T17:12
89 schema:sdLicense https://scigraph.springernature.com/explorer/license/
90 schema:sdPublisher N2278639c240845d79d3c58e204898c68
91 schema:url https://doi.org/10.1007/s13300-022-01264-6
92 sgo:license sg:explorer/license/
93 sgo:sdDataset articles
94 rdf:type schema:ScholarlyArticle
95 N2278639c240845d79d3c58e204898c68 schema:name Springer Nature - SN SciGraph project
96 rdf:type schema:Organization
97 N329e70b55db248bb9559432e9fb9cd6a rdf:first sg:person.01171720750.21
98 rdf:rest N871942223aec45d886d55f48912b3018
99 N44a94ee3455f492c938ce09afa0c0b83 schema:affiliation grid-institutes:grid.476461.6
100 schema:familyName Rubio de Santos
101 schema:givenName Miriam
102 rdf:type schema:Person
103 N70218b5447104317b5ba1b760b1dc2b2 rdf:first N44a94ee3455f492c938ce09afa0c0b83
104 rdf:rest Nf99c38f4f45443eeb8f66c454aef2b61
105 N7096ca6eb1034299b900344cc433763e rdf:first sg:person.0730410761.59
106 rdf:rest rdf:nil
107 N70d7a496860643b491ea2bc714c1a0e2 schema:name doi
108 schema:value 10.1007/s13300-022-01264-6
109 rdf:type schema:PropertyValue
110 N72e23a81368040d0a6abbbe77b078ac5 schema:issueNumber 6
111 rdf:type schema:PublicationIssue
112 N7865e0168f4d47e7a6bff5d254eaeb28 rdf:first sg:person.0643342424.21
113 rdf:rest N329e70b55db248bb9559432e9fb9cd6a
114 N871942223aec45d886d55f48912b3018 rdf:first sg:person.016704660465.17
115 rdf:rest N7096ca6eb1034299b900344cc433763e
116 Na6cf39471be74907b05c1011a3d5d85f schema:volumeNumber 13
117 rdf:type schema:PublicationVolume
118 Nc8f3e9b61dc6421a920e1dabf55eca72 rdf:first sg:person.01076730565.35
119 rdf:rest N7865e0168f4d47e7a6bff5d254eaeb28
120 Nddc5f331f5274f638ac5e596cb32a7d6 schema:name dimensions_id
121 schema:value pub.1147289631
122 rdf:type schema:PropertyValue
123 Ne902d5b6c4374128a5493d3d2e350aa9 schema:name pubmed_id
124 schema:value 35449431
125 rdf:type schema:PropertyValue
126 Nf99c38f4f45443eeb8f66c454aef2b61 rdf:first sg:person.07555754123.78
127 rdf:rest Nc8f3e9b61dc6421a920e1dabf55eca72
128 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
129 schema:name Medical and Health Sciences
130 rdf:type schema:DefinedTerm
131 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
132 schema:name Clinical Sciences
133 rdf:type schema:DefinedTerm
134 sg:journal.1044057 schema:issn 1869-6953
135 1869-6961
136 schema:name Diabetes Therapy
137 schema:publisher Springer Nature
138 rdf:type schema:Periodical
139 sg:person.01076730565.35 schema:affiliation grid-institutes:grid.476461.6
140 schema:familyName Duque
141 schema:givenName Natalia
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076730565.35
143 rdf:type schema:Person
144 sg:person.01171720750.21 schema:affiliation grid-institutes:None
145 schema:familyName Spaepen
146 schema:givenName Erik
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171720750.21
148 rdf:type schema:Person
149 sg:person.016704660465.17 schema:affiliation grid-institutes:None
150 schema:familyName Carreño
151 schema:givenName Ágata
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016704660465.17
153 rdf:type schema:Person
154 sg:person.0643342424.21 schema:affiliation grid-institutes:grid.476461.6
155 schema:familyName Díaz-Cerezo
156 schema:givenName Silvia
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643342424.21
158 rdf:type schema:Person
159 sg:person.0730410761.59 schema:affiliation grid-institutes:grid.411171.3
160 schema:familyName Fernández
161 schema:givenName Alberto
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730410761.59
163 rdf:type schema:Person
164 sg:person.07555754123.78 schema:affiliation grid-institutes:grid.476461.6
165 schema:familyName Artime
166 schema:givenName Esther
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07555754123.78
168 rdf:type schema:Person
169 grid-institutes:None schema:alternateName HaaPACS GmbH, Schriesheim, Germany
170 IQVIA, Madrid, Spain
171 schema:name HaaPACS GmbH, Schriesheim, Germany
172 IQVIA, Madrid, Spain
173 rdf:type schema:Organization
174 grid-institutes:grid.411171.3 schema:alternateName Department of Endocrinology and Nutrition, Móstoles University Hospital, Madrid, Spain
175 schema:name Department of Endocrinology and Nutrition, Móstoles University Hospital, Madrid, Spain
176 rdf:type schema:Organization
177 grid-institutes:grid.476461.6 schema:alternateName Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, Spain
178 schema:name Eli Lilly and Company, Avda. de la Industria 30, Alcobendas, 28108, Madrid, Spain
179 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...